National Board of Examinations

DNB Dermatology Venereology and Leprosy **Question Paper Name:** Paper2 **DNB Dermatology Venereology and Leprosy Subject Name:** Paper2 **Creation Date:** 2023-10-15 14:13:54 **Duration:** 180 **Share Answer Key With Delivery Engine:** No **Actual Answer Key:** No **DNB Dermatology Venereology and Leprosy Paper2 Group Number:** 1 Group Id: 3271872484 **Group Maximum Duration:** 0 **Group Minimum Duration:** 180 **Show Attended Group?:** No **Edit Attended Group?:** No 100 **Group Marks:** Is this Group for Examiner?: No **Cant View Examiner permission: Show Progress Bar?:** No

DNB Dermatology Venereology and Leprosy Paper2

Section Id: 3271872487

Section Number:

Section type: Offline

Mandatory or Optional: Mandatory

Number of Questions to be attempted: 10

Section Marks: 100

Enable Mark as Answered Mark for Review and

Clear Response:

Yes

Maximum Instruction Time: 0

Sub-Section Number: 1

Sub-Section Id: 3271872491

Question Shuffling Allowed: No

Is Section Default?: null

Question Number: 1 Question Id: 32718725073 Question Type: SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time:0

Correct Marks: 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

- 1. a) Histopathology of scleroderma & scleromyxedema. [5]
- b) Paraneoplastic pemphigus. [5]

Question Number: 2 Question Id: 32718725074 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

Diagnostic approach:

a) Mycetoma. [5]

b) PKDL. [5]

Question Number: 3 Question Id: 32718725075 Question Type: SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Role of dupilumab in atopic dermatitis. [5]

b) Systemic contact dermatitis. [5]

Question Number: 4 Question Id: 32718725076 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Cutaneous manifestations of sarcoidosis. [5]

b) Syndromic ichthyosis. [5]

Question Number: 5 Question Id: 32718725077 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Grenz zone. [5]

b) Extragenital LSEA. [5]

Question Number: 6 Question Id: 32718725078 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Orofacial granulomatosis. [5]

b) Biofilms. [5]

Question Number: 7 Question Id: 32718725079 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Trichoscopic findings in lichen planopilaris & discoid lupus erythematosus. [5]

b) Lupus profundus. [5]

Question Number: 8 Question Id: 32718725080 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Physiological skin changes in newborn. [5]

b) Tuberculides: clinical types & management. [5]

Question Number: 9 Question Id: 32718725081 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

Discuss rosacea under following headings:

a) Clinical subtypes. [4]

b) Medical & surgical treatment. [6]

Question Number: 10 Question Id: 32718725082 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Management of non-tuberculous mycobacterial infections. [6]

b) Kikuchi-Fujimoto disease. [4]